---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-019738"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2023-01-31T23:59:59+00:00"
generated_at: "2026-06-20T04:47:12.808282+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Inovio cuts 11% of workforce, expects $4.3M annual savings; securities class action settled for $44M

## Summary
- Reduced headcount by 24 employees (11% of full-time staff); one-time charge of $1.1M in Q1 2023.
- Expected annual savings of ~$4.3M from reorganization and prior program discontinuations.
- Court granted final approval of $44M securities class action settlement: $30M cash (paid by insurers) plus $14M in stock (initially 7M shares; <5% of outstanding).
- Key data readouts expected Q1 2023 for INO-3107 (RRP) and VGX-3100 (cervical HSIL) trials.
- Restructuring redirects resources to lead DNA medicine candidates; 2022 Q4 results planned for March 2023.

## SEC filing metadata
- accession: 0001193125-23-019738
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2023-01-31T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.05, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000119312523019738/0001193125-23-019738-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000119312523019738/d295438d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-019738
- JSON: https://secwatch.observer/filing/0001193125-23-019738.json
- Plain text: https://secwatch.observer/filing/0001193125-23-019738.txt

## Key facts
- Restructurings & Charges
  INOVIO PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $1.1 million (approximately 24 employees).
  - Type: restructuring
  - Charge: approximately $1.1 million
  - Headcount: approximately 24 employees
  source text: On January 31, 2023, Inovio Pharmaceuticals, Inc. (the “ Company ”) committed to and communicated a corporate reorganization plan, including a reduction in force (the “ Reduction ”). The purpose of the Reduction is to decrease expenses and maintain a streamlined organization to support key clinical programs that are expected to drive long-term growth. As part of the Reduction, the Company has reduced its overall headcount by approximately 24 employees, which represents 11% of its full-time employees. Along with other planned cost-saving measures, the Reduction is expected to provide annual savings of approximately $4.3 million. The Company expects to incur a one-time pre-tax charge of approximately $1.1 million in the first quarter of 2023 related to the Reduction
  evidence_url: https://www.sec.gov/Archives/edgar/data/1055726/000119312523019738/0001193125-23-019738-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.